HIV and hepatobiliary disease

Abstract Liver disease is an increasingly important cause of morbidity and mortality in patients with HIV/AIDS. With the availability of highly active anti-retroviral therapy (HAART), there has been a change in the pattern of liver disease seen. Although opportunistic infections and neoplasms are still seen, co-infection with hepatitis viruses, especially HCV, is now emerging as the most significant cause of liver disease in this group of patients. In addition, drug-induced liver damage is becoming more prevalent due to the increased complexity and toxicity of the HAART regimens used.